European Archives - Page 434 of 1131 - European Medical Journal

NUVAXOVIDᵀᴹ dispersion for injection COVID-19 Vaccine (recombinant, adjuvanted) For Individuals 12 Years and Older - Switzerland

Learn about the clinical efficacy and safety data for a new recombinant protein subunit COVID-19 vaccine approved and available.

Interview: Peter Gill

Peter Gill | Staff Paediatrician and Associate Scientist, The Hospital for Sick Children and SickKids Research Institute, Toronto, Canada; Assistant Professor, Department of Paediatrics and Institute of Health Policy, Management and Evaluation, University of Toronto, Canada

Interview: Damian Roland

Damian Roland | Head of Service, Children’s Emergency Department, Leicester Royal Infirmary, UK; Honorary Professor, Population Health Sciences, University of Leicester, UK

Embedding Research into Clinical Practice

Ai Lyn Tan joins Jonathan to discuss rheumatology research and its use clinical practice, as well as the emotional burden of arthritis.

Editor's Pick: Therapeutic Biomarkers for Bladder Carcinoma

Bladder cancer (BC) is the fourth most common malignancy in males and shows high prevalence and mortality rates worldwide despite improvements in its management.

Breaking the bias in healthcare AI

The future is brimming with possibilities for AI in healthcare, but eliminating bias is imperative, so where should pharma start?

Neutrophil-Lymphocyte Ratio, Platelets-Lymphocyte Ratio, and High-Resolution CT in Patients with COVID-19

COVID-19 is an abruptly progressing and sometimes lethal contagious disease. It is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which was first reported in Wuhan, China, at the end of 2019. The World Health Organization (WHO) announced it as a pandemic in March 2020.

Infographic: 5 Key Reasons: All Infants Need Protection from RSV

Infographic: 5 Key Reasons: All Infants Need Protection from RSV. This educational activity is sponsored by Sanofi.

Medical affairs, AI and insight generation

AI holds buckets of potential for medical affairs teams, but it must be adopted considerately and correctly to meet their needs.

Super reps, ChatGPT and pharma’s future on social media

Isabel chats to Darshan Kulkarni, regulatory and compliance attorney for the Life Sciences, about key marketing and medical affairs trends.